Want to see OCGN full AI Analyst Report?
Top Page
Ocugen
(NASDAQ:OCGN)
Select Model
Select Model
Rating:47Neutral
Price Target:
$1.50
▼(-24.62% Downside)
Action:Reiterated
Date:06/27/26
The score is held down primarily by weak financial performance (small revenue base, large ongoing losses, sustained cash burn, and a stressed balance sheet with higher leverage and thin equity). Technicals are mixed with some near-term strength but weaker longer-term trend signals, while valuation is limited by ongoing losses and no dividend support. Corporate events provide a partial offset as the convertible financing improves liquidity and runway, albeit with dilution risk.
Positive Factors
Late-stage ophthalmic pipeline
Ocugen has multiple late-stage ophthalmic programs with completed enrollments and positive 12‑month Phase 2 data showing a 31% lesion reduction. Successful regulatory submissions or approvals would create durable, one-time gene therapy revenue streams and reposition the company from research to potential commercial execution.
Negative Factors
Persistent operating losses
The company remains deeply unprofitable with recurring negative operating and free cash flow across periods. Sustained cash burn forces ongoing dependence on external financing and creates execution risk if future capital markets access or milestone funding becomes constrained, limiting long‑term financial resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Late-stage ophthalmic pipeline
Ocugen has multiple late-stage ophthalmic programs with completed enrollments and positive 12‑month Phase 2 data showing a 31% lesion reduction. Successful regulatory submissions or approvals would create durable, one-time gene therapy revenue streams and reposition the company from research to potential commercial execution.
Read all positive factors
Ocugen (OCGN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$507.78M
Dividend YieldN/A
Average Volume (3M)8.49M
Price to Earnings (P/E)―
Beta (1Y)1.11
Revenue Growth-1.26%
EPS Growth-23.97%
CountryUS
Employees116
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.24
Shares Outstanding338,521,850
10 Day Avg. Volume11,894,759
30 Day Avg. Volume8,491,037
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)-33.31
Price to Sales (P/S)91.83
P/FCF Ratio-7.09
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue93.58
Enterprise Value/Gross Profit93.58
Enterprise Value/Ebitda-6.63
Forecast
1Y Price Target
$9.67Price Target Upside385.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.22
Revenue Forecast (FY)$4.38M
Ocugen Business Overview & Revenue Model
Company Description
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features sev...
How the Company Makes Money
Ocugen is a clinical-stage company and, as such, its ability to generate recurring product revenue is limited; its business model primarily depends on external capital and, when available, collaboration-related income. In general, the company can ...
Ocugen Earnings Call Summary
Earnings Call Date:Mar 04, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Jul 31, 2026
Earnings Call Sentiment Positive
The call conveyed substantial scientific and operational progress across multiple gene‑therapy programs (OCU400, OCU410, OCU410ST) including completed Phase 3 enrollment, strong early efficacy signals (46% lesion reduction, 50% responder rate, ~two-line LLVA gain, 60% slower EZ loss), a peer‑reviewed publication, a regional licensing deal, recent capital raise, and senior hires to support commercialization. Counterbalancing these positives are a limited cash runway into 2026 (dependence on uncertain warrant exercise and future financings), rising R&D spend (~24% year) and small/preliminary datasets that require confirmatory Phase 3 results. Overall, the highlights (clinical progress, regulatory alignment, partnerships, fundraising, leadership additions) meaningfully outweigh the risks, though execution and financing remain key near‑term priorities.Positive Updates
OCU400 Phase 3 Enrollment Complete
Limelight Phase 3 enrollment complete with 140 patients randomized 2:1 (treatment:control); gene-agnostic design covering major mutations (e.g., USH2A, XLRP, PDE6B). Top-line one‑year data expected in 2027, rolling BLA submission planned to begin in 2026 and potential commercialization targeted in 2027.
Negative Updates
Short Cash Runway and Financing Reliance
Reported cash and cash equivalents extend runway only into 2026 unless additional financing occurs. Ongoing reliance on potential $30.0M warrant exercises (uncertain) and licensing milestones to extend runway into 2027 introduces liquidity risk.
Read all updates
Q4-2025 Updates
Positive
Negative
OCU400 Phase 3 Enrollment Complete
Limelight Phase 3 enrollment complete with 140 patients randomized 2:1 (treatment:control); gene-agnostic design covering major mutations (e.g., USH2A, XLRP, PDE6B). Top-line one‑year data expected in 2027, rolling BLA submission planned to begin in 2026 and potential commercialization targeted in 2027.
Read all positive updates
Company Guidance
Management gave specific numerical guidance and timelines: OCU400 (Limelight) completed enrollment (n=140, randomized 2:1), uses a one‑year primary LDNA endpoint (clinically meaningful ≥1 lux), is on track to begin a rolling BLA in 2026 (Q3 cited), with top‑line data and potential approval/commercialization in 2027; OCU410 (GA) released preliminary 12‑month Phase 2 data showing a 46% lesion‑growth reduction versus control (p=0.015, cohort n=23), a 50% responder rate (>50% lesion reduction), subgroup ≥7.5 mm² with 56–57% reductions, and a Phase‑1 observation of 60% slower EZ loss, with full Phase 2 data due this month and Phase 3 planned in 2026; OCU410ST (Stargardt) is ahead of schedule with enrollment expected complete in early‑2026, an adaptive masked interim analysis of 24 subjects (16 treatment/8 control) planned in Q3 and top‑line Phase 2/3 data and a BLA path targeted in 2027, with EZ exploratory results showing ~16% lesion reduction and 50% of treated eyes achieving EZ preservation at 12 months; other programs: OCU200 enrollment expected complete in 2026 and OCU500 Phase‑1 initiation by NIAID in 2026; and financial guidance: FY2025 R&D $39.8M (Q4 $10.7M), G&A $27.6M (Q4 $6.1M), FY2025 net loss per share $0.23 (Q4 $0.06), cash runway into 2026 supported by a $22.5M registered direct raise and a potential extension into 2027 if $30M of warrants are fully exercised, with management reiterating a plan to file three BLAs in the next three years.Ocugen Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
24
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.46M | 4.41M | 4.05M | 6.04M | 2.49M | 0.00 |
| Gross Profit | 4.46M | 2.02M | 2.09M | 5.33M | 2.49M | 0.00 |
| EBITDA | -63.06M | -60.27M | -52.09M | -62.37M | -86.32M | -58.11M |
| Net Income | -71.67M | -67.85M | -54.05M | -63.08M | -86.80M | -58.37M |
Balance Sheet | ||||||
| Total Assets | 56.91M | 43.52M | 82.44M | 64.55M | 108.63M | 105.76M |
| Cash, Cash Equivalents and Short-Term Investments | 31.86M | 18.57M | 58.51M | 39.46M | 90.93M | 94.96M |
| Total Debt | 33.30M | 33.14M | 32.50M | 6.94M | 6.37M | 3.31M |
| Total Liabilities | 51.10M | 55.68M | 52.81M | 23.98M | 34.65M | 9.94M |
| Stockholders Equity | 5.80M | -12.17M | 29.63M | 40.56M | 73.98M | 95.82M |
Cash Flow | ||||||
| Free Cash Flow | -59.58M | -57.15M | -45.53M | -72.53M | -64.54M | -48.88M |
| Operating Cash Flow | -59.40M | -56.96M | -42.14M | -62.05M | -60.08M | -47.94M |
| Investing Cash Flow | -215.00K | -311.00K | -3.38M | 3.08M | -16.97M | -1.82M |
| Financing Cash Flow | 53.56M | 17.33M | 64.86M | 20.88M | 59.48M | 120.68M |
Ocugen Technical Analysis
Neutral
1.99
Price Trends
1.42
Positive
1.64
Negative
1.55
Negative
Market Momentum
0.04
Negative
53.77
Neutral
39.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OCGN, the sentiment is Neutral. The current price of 1.99 is above the 20-day moving average (MA) of 1.38, above the 50-day MA of 1.42, and above the 200-day MA of 1.55, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 53.77 is Neutral, neither overbought nor oversold. The STOCH value of 39.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OCGN.
Ocugen Risk Analysis
Ocugen disclosed 6 risk factors in its most recent earnings report. Ocugen reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ocugen Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $507.78M | -6.31 | -9999.00% | ― | -1.26% | -23.97% | |
| ― | $460.27M | -7.80 | -1.13% | 0.00% | 6.82% | -165.65% | |
68 Neutral | $795.54M | 27.15 | 30.21% | ― | 13.16% | ― | |
62 Neutral | $1.88B | -13.82 | -63.58% | ― | -61.87% | 10.39% | |
55 Neutral | $2.03B | -13.18 | -40.99% | ― | -73.07% | -2335.85% | |
42 Neutral | $162.80M | -1.24 | 65.27% | ― | 4.43% | 27.41% |
* Healthcare Sector Average
OCGN
Ocugen
1.47
0.33
28.95%
SVA
Sinovac Biotech
6.47
0.00
0.00%
XOMA
XOMA Royalty Corporation
44.80
17.66
65.07%
ADCT
ADC Therapeutics
1.30
-1.85
-58.73%
GLUE
Monte Rosa Therapeutics
24.52
19.36
375.19%
ABSI
AbSci
11.47
8.80
329.59%
Ocugen Corporate Events
Executive/Board ChangesShareholder Meetings
Ocugen Stockholders Approve Proposals and Confirm Leadership
Positive
Jun 11, 2026
On June 11, 2026, Ocugen held its 2026 Annual Meeting of Stockholders virtually, where shareholders elected Kirsten Castillo and Satish Chandran as Class III directors to serve until the 2029 annual meeting and ratified PricewaterhouseCoopers LLP ...
Executive/Board Changes
Ocugen Consolidates Financial Leadership Under New Accounting Officer
Neutral
Jun 3, 2026
Ocugen, Inc. reported that Chief Accounting Officer Ramesh Ramachandran resigned effective May 29, 2026, where he had served as the company’s principal accounting officer. The move marks a notable change in the finance leadership structure a...
Business Operations and StrategyPrivate Placements and Financing
Ocugen Raises $130 Million Through Convertible Notes Offering
Positive
May 14, 2026
On May 7, 2026, Ocugen closed a private offering of $115 million in 6.75% Convertible Senior Notes due 2034 and, on May 14, 2026, issued an additional $15 million after the full exercise of the over-allotment option, bringing the total to $130 mil...
Business Operations and StrategyExecutive/Board Changes
Ocugen Announces Interim Chief Medical Officer Appointment Transition
Neutral
May 14, 2026
On May 8, 2026, Ocugen, Inc. saw the departure of its Chief Medical Officer, Huma Qamar, M.D., MPH, CMI, marking a notable change in the company’s senior medical leadership structure. On the same date, Ocugen appointed Mohamed Genead, M.D., ...
Business Operations and StrategyPrivate Placements and Financing
Ocugen Raises Capital Through Convertible Senior Notes Offering
Positive
May 7, 2026
On May 7, 2026, Ocugen, Inc. completed a private offering of $115 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034, issued as unsecured senior obligations with detailed conversion, redemption and default provisions. Th...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Ocugen Advances Late-Stage Gene Therapies, Bolsters Cash Runway
Positive
May 5, 2026
Ocugen, Inc., based in Malvern, Pa., is a biotechnology company focused on gene therapies for blindness diseases, including retinitis pigmentosa, Stargardt disease and geographic atrophy secondary to dry age-related macular degeneration, as well a...
Business Operations and StrategyPrivate Placements and Financing
Ocugen Announces Private Convertible Notes Offering to Deleverage
Positive
May 4, 2026
On May 4, 2026, Ocugen announced a private offering of convertible notes, including an option for the initial purchaser to buy up to an additional $15 million of notes within 13 days of issuance, as part of broader efforts to strengthen its balanc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.